Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORPHEUS-NEO HCC: Neoadjuvant Immunotherapy Combinations in Resectable Hepatocellular Carcinoma
NCT05908786Phase 2Terminated
- Sponsor
- Roche
- Start
- Dec 2023
- Primary completion
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 6
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab, tiragolumab, tobemstomig in hepatocellular carcinoma (HCC), sponsored by Roche. Started Dec 2023; status: terminated.
02
Drugs
atezolizumabbevacizumabtiragolumabtobemstomig
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05908786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05908786.